WO1997020579A2 - Novel compounds and use - Google Patents
Novel compounds and use Download PDFInfo
- Publication number
- WO1997020579A2 WO1997020579A2 PCT/EP1996/005477 EP9605477W WO9720579A2 WO 1997020579 A2 WO1997020579 A2 WO 1997020579A2 EP 9605477 W EP9605477 W EP 9605477W WO 9720579 A2 WO9720579 A2 WO 9720579A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- conjugate according
- fragment
- neurotoxin
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
Definitions
- the present invention relates to novel therapeutic conjugates and their use in targeting therapeutic substances, in particular nucleic acids, to the central nervous system.
- therapeutic substances in particular nucleic acids
- Large molecules introduced into the body systemically or into peripheral tissues are not transported into the nervous system in therapeutically significant amounts as they are unable to cross the so-called 'blood brain barrier'.
- Hence the direct therapeutic application of large molecules such as nucleic acids is currently not feasible.
- Some neurotoxins have specific properties that allow them to invade the vertebrate nervous system. They bind specifically to the surface of neurons, which are the primary cellular elements of the nervous system. The neurotoxin is internalised, and retrogradely transported by those neurons to the neuronal cell body. The neurotoxin may also be transported transneuronally to second order neurons in the nervous system. In some cases it has been shown that the properties which allow transport ofthe neurotoxin are conferred by a particular fragment of the toxin. Examples of such toxins are clostridial neurotoxins such as those from Tetanus and Botulinum, and snake toxins such as crotoxin and dendrotoxin, from the rattlesnake and mamba snake respectively.
- HRP horse radish peroxidase
- the present invention relates to the use of neurotoxins to transport therapeutically active nucleic acids across the blood brain barrier into the nervous system.
- the present invention provides a novel conjugate comprising a neurotoxin or a fragment thereof and a nucleic acid.
- the conjugate of the invention may also be referred to herein as the compound ofthe invention.
- the neurotoxins employed in the present invention may be any suitable neurotoxin which has the ability to cross the blood-brain barrier.
- the neurotoxin may be derived from bacteria, such as Tetanus or Bolulinum toxin; or from snakes, such as crotoxin or dendrotoxin; or it may be a fragment of such toxins.
- a neurotoxin fragment can be prepared by methods well known in the protein art, for example by proteolytic cleavage or by genetic engineering strategies. Said fragment is preferably a non-toxic binding fragment.
- the nucleic acids may be single or double stranded DNA or RNA molecules, either circular or linear in form, encoding either whole genes, cDNAs, non-coding sequence, genetic control regions, or antisense constructs.
- the nucleic acid preferably exerts a therapeutic effect.
- the conjugation may be chemical in nature using chemical linkers such as poly ⁇ lysine, or covalent linkers.
- Other protein, nucleic acid, or other molecular components may also be part ofthe total conjugate, so as to endow the conjugate with other properties. For example, other components such as haemoglutinin might be included that aid trasport from the lysosomal compartment, or nuclear localisation sequences might aid transport into the nucleus.
- Conjugates according to the present invention may be prepared by conventional methods known in the art.
- conjugates may be introduced into either the somatic (i.e. non-neural) or neural tissue of patients using methods known in the art, typically by hypodermic injection.
- somatic i.e. non-neural
- neural tissue typically by hypodermic injection.
- the conjugate will exert a therapeutic effect.
- the invention therefore further provides a pharmaceutical composition
- a pharmaceutical composition comprising a conjugate ofthe invention and a pharmaceutically acceptable carrier.
- the conjugate will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form ofthe composition will depend on the mode of administration.
- the conjugate may, for example, be employed in the form of an aerosol or nebulisable solution for inhalation or a sterile solution for parenteral administration, intra-articuiar administration or intra-cranial administration.
- the dosage ranges for administration ofthe compounds ofthe present invention are those to produce the desired therapeutic effect.
- Suitable daily dosages are in the range 0.01-l Omg/kg, eg 0.01- 5mg/kg, more particularly 0.02-1.5mg/kg, eg 0.04- 1.5mg/kg.
- the unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to lOOmg eg 1 to 50 mg per dose, which may be administered in one or more doses, such as one to six doses per day, Wide variations in the required dosage, however, are to be expected in view ofthe variety of nucleic acids available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.
- Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
- Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle.
- the compound depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
- Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area.
- the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
- Parenteral suspensions suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration.
- the compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation.
- a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution ofthe compound.
- Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation.
- compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
- a method of treating a condition or disease which is susceptible of treatment with a nucleic acid in a mammal e.g. a human which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention.
- a condition or disease which is susceptible of treatment with a nucleic acid may be for example a condition or disease which may be treated by or requiring gene therapy.
- the invention further provides a compound ofthe invention for use as an active therapeutic substance, in particular for use in treating a condition or disease which is susceptible of treatment with a nucleic acid eg a condition or disease requiring or treatable by gene therapy.
- the invention also provides the use of a compound of the invention in the manufacture of a medicament for treating a condition or disease which is susceptible of treatment with a nucleic acid eg a condition or disease requiring or treatable by gene therapy.
- the invention also provides the use of a conjugate according to the present invention for the manufacture of a medicament for transporting nucleic acids to the central nervous system.
- the invention also provides a therapeutic delivery system comprising a neurotoxin or a fragment thereof and a nucleic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of neurotoxins or fragments thereof to transport nucleic acids into the nervous system and conjugates comprising a neurotoxin or a fragment thereof and a nucleic acid.
Description
NOVEL COMPOUNDS AND USE
The present invention relates to novel therapeutic conjugates and their use in targeting therapeutic substances, in particular nucleic acids, to the central nervous system. Large molecules introduced into the body systemically or into peripheral tissues are not transported into the nervous system in therapeutically significant amounts as they are unable to cross the so-called 'blood brain barrier'. Hence the direct therapeutic application of large molecules such as nucleic acids is currently not feasible.
Some neurotoxins have specific properties that allow them to invade the vertebrate nervous system. They bind specifically to the surface of neurons, which are the primary cellular elements of the nervous system. The neurotoxin is internalised, and retrogradely transported by those neurons to the neuronal cell body. The neurotoxin may also be transported transneuronally to second order neurons in the nervous system. In some cases it has been shown that the properties which allow transport ofthe neurotoxin are conferred by a particular fragment of the toxin. Examples of such toxins are clostridial neurotoxins such as those from Tetanus and Botulinum, and snake toxins such as crotoxin and dendrotoxin, from the rattlesnake and mamba snake respectively.
The transport properties of neurotoxins have been utilized to target proteins to the nervous system, by conjugating or otherwise linking the toxin or toxin fragment to such molecules, for example the enzyme horse radish peroxidase (HRP) (PS Fishman et al., J. Neurol. Sci., 1990, 98: 311-325), and wheat germ agglutinin.
In one aspect the present invention relates to the use of neurotoxins to transport therapeutically active nucleic acids across the blood brain barrier into the nervous system. In a further aspect the present invention provides a novel conjugate comprising a neurotoxin or a fragment thereof and a nucleic acid. The conjugate of the invention may also be referred to herein as the compound ofthe invention.
The neurotoxins employed in the present invention may be any suitable neurotoxin which has the ability to cross the blood-brain barrier. Thus for example the neurotoxin may be derived from bacteria, such as Tetanus or Bolulinum toxin; or from snakes, such as crotoxin or dendrotoxin; or it may be a fragment of such toxins. A neurotoxin fragment can be prepared by methods well known in the protein art, for example by proteolytic cleavage or by genetic engineering strategies. Said fragment is preferably a non-toxic binding fragment.
The nucleic acids may be single or double stranded DNA or RNA molecules, either circular or linear in form, encoding either whole genes, cDNAs, non-coding sequence, genetic control regions, or antisense constructs. The nucleic acid preferably exerts a therapeutic effect.
The conjugation may be chemical in nature using chemical linkers such as poly¬ lysine, or covalent linkers. Other protein, nucleic acid, or other molecular components may also be part ofthe total conjugate, so as to endow the conjugate with other properties. For example, other components such as haemoglutinin might be included that aid trasport from the lysosomal compartment, or nuclear localisation sequences might aid transport into the nucleus. Conjugates according to the present invention may be prepared by conventional methods known in the art.
Such conjugates may be introduced into either the somatic (i.e. non-neural) or neural tissue of patients using methods known in the art, typically by hypodermic injection. By the specific binding, internalisation, and retrograde transport ofthe conjugate into the nervous system, the conjugate will exert a therapeutic effect.
The invention therefore further provides a pharmaceutical composition comprising a conjugate ofthe invention and a pharmaceutically acceptable carrier.
In use the conjugate will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form ofthe composition will depend on the mode of administration. The conjugate may, for example, be employed in the form of an aerosol or nebulisable solution for inhalation or a sterile solution for parenteral administration, intra-articuiar administration or intra-cranial administration. The dosage ranges for administration ofthe compounds ofthe present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the choice of nucleic acid, the precise nature ofthe conjugate, the route of administration, the nature ofthe formulation, the age ofthe patient, the nature, extent or severity ofthe patient's condition, contraindications, if any, and the judgment of the attending physician. Suitable daily dosages are in the range 0.01-l Omg/kg, eg 0.01- 5mg/kg, more particularly 0.02-1.5mg/kg, eg 0.04- 1.5mg/kg. The unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to lOOmg eg 1 to 50 mg per dose, which may be administered in one or more doses, such as one to six doses per day, Wide variations in the required dosage, however, are to be expected in view ofthe variety of nucleic acids available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art. Compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
- 9 .
Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and/or local anaesthetic agents may be dissolved in the vehicle.
Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area. Alternatively the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection, are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation. Advantageously, a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution ofthe compound. Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices. In a further aspect there is provided a method of treating a condition or disease which is susceptible of treatment with a nucleic acid in a mammal e.g. a human which comprises administering to the sufferer an effective, non-toxic amount of a compound of the invention. A condition or disease which is susceptible of treatment with a nucleic acid may be for example a condition or disease which may be treated by or requiring gene therapy.
The invention further provides a compound ofthe invention for use as an active therapeutic substance, in particular for use in treating a condition or disease which is
susceptible of treatment with a nucleic acid eg a condition or disease requiring or treatable by gene therapy.
The invention also provides the use of a compound of the invention in the manufacture of a medicament for treating a condition or disease which is susceptible of treatment with a nucleic acid eg a condition or disease requiring or treatable by gene therapy.
In a further aspect the invention also provides the use of a conjugate according to the present invention for the manufacture of a medicament for transporting nucleic acids to the central nervous system. The invention also provides a therapeutic delivery system comprising a neurotoxin or a fragment thereof and a nucleic acid.
No unexpected toxicological effects are expected when compounds ofthe invention are administered in accordance with the present invention.
Claims
1. Use of a neurotoxin or a fragment thereof to transport a nucleic acid into the nervous system.
2. Use according to claim 1 wherein the nucleic acid exerts a therapeutic effect.
3. Use accoding to claim 1 or claim 2 wherein the neurotoxin is selected from a bacterial or snake toxin or a fragment thereof.
4. Use acording to any of claims 1 to 3 wherein the neurotoxin fragment is a non-toxic binding fragment.
5. A conjugate comprising a neurotoxin or a fragment thereof and a nucleic acid.
6. A conjugate according to claim 5 wherein the neurotoxin is selected from a bacterial or snake toxin or a fragment thereof.
7. A conjugate according to claim 5 or 6 wherein the neurotoxin fragment is obtained by proteolytic cleavage.
8. A conjugate according to claim 5 or 6 wherein the neurotoxin fragment is obtained by a recombinant method.
9. A conjugate according to any of claims 5 to 8 wherein the nucleic acid is a single or double stranded DNA or RNA molecule.
10. A conjugate according to claim 9 wherein the nucleic acid encodes a whole gene.
1 1. A conjugate according to claim 9 wherein the nucleic acid encodes a cDNA.
12. A conjugate according to any of claims 5 to 1 1 wherein conjugation is effected by a chemical linker.
13. A conjugate according to any of claims 5 to 1 1 wherein conjugation is effected by a covalent linker.
14. A pharmaceutical composition comprising a conjugate according to any of claims 5 to 13 and a pharmaceutically acceptable carrier therefor.
15. A conjugate ofthe invention for use as an active therapeutic substance.
16. A method of treating a condition or disease which is susceptible of treatment with a nucleic acid in a mammal which method comprises administering to the sufferer an effective, non-toxic amount of a conjugate according to the invention.
17. Use of a conjugate according to the invention in the manufacture of a medicament for treating a a condition or disease which is susceptible of treatment with a nucleic acid.
18. Use of a conjugate according to the invention in the manufacture of a medicament for transporting a nucleic acid to the central nervous system.
19. A therapeutic delivery system comprising a neurotoxin or a fragment thereof and a nucleic acid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9524807.6 | 1995-12-05 | ||
| GBGB9524807.6A GB9524807D0 (en) | 1995-12-05 | 1995-12-05 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997020579A2 true WO1997020579A2 (en) | 1997-06-12 |
| WO1997020579A3 WO1997020579A3 (en) | 1997-09-25 |
Family
ID=10784907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/005477 WO1997020579A2 (en) | 1995-12-05 | 1996-12-02 | Novel compounds and use |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB9524807D0 (en) |
| WO (1) | WO1997020579A2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000033880A3 (en) * | 1998-12-04 | 2000-10-12 | Deutsches Krebsforsch | Conjugate used for enriching in neuronal cells |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| WO2009083738A2 (en) * | 2007-12-31 | 2009-07-09 | Syntaxin Limited | Rna delivery vehicles |
| US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
| US8541384B2 (en) | 2002-07-24 | 2013-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
| US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US10064921B2 (en) | 2003-10-29 | 2018-09-04 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8914984D0 (en) * | 1989-06-29 | 1989-08-23 | Animal Health Inst | Nucleotide sequences |
| WO1995032738A1 (en) * | 1994-05-31 | 1995-12-07 | Allergan, Inc. | Modification of clostridial toxins for use as transport proteins |
| AU3275595A (en) * | 1994-08-05 | 1996-03-04 | Molecular/Structural Biotechnologies, Inc. | Site-specific biomolecular complexes |
-
1995
- 1995-12-05 GB GBGB9524807.6A patent/GB9524807D0/en active Pending
-
1996
- 1996-12-02 WO PCT/EP1996/005477 patent/WO1997020579A2/en active Application Filing
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000033880A3 (en) * | 1998-12-04 | 2000-10-12 | Deutsches Krebsforsch | Conjugate used for enriching in neuronal cells |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| WO2003087367A2 (en) * | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| WO2003087367A3 (en) * | 2002-04-18 | 2004-04-29 | Lynkeus Biotech Gmbh | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| WO2003087368A3 (en) * | 2002-04-18 | 2004-04-29 | Lynkeus Bio Tech Gmbh | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| US8202845B2 (en) | 2002-04-18 | 2012-06-19 | Acuity Pharmaceuticals, Inc. | Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification |
| US8546345B2 (en) | 2002-07-24 | 2013-10-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
| US9150863B2 (en) | 2002-07-24 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
| US8946403B2 (en) | 2002-07-24 | 2015-02-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
| US8541384B2 (en) | 2002-07-24 | 2013-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
| US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
| US9238061B2 (en) | 2003-10-29 | 2016-01-19 | Allergan, Inc. | Botulinum toxin treatment of anxiety and bipolar disorders |
| US10064921B2 (en) | 2003-10-29 | 2018-09-04 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| WO2009083738A3 (en) * | 2007-12-31 | 2009-08-27 | Syntaxin Limited | Rna delivery vehicles |
| WO2009083738A2 (en) * | 2007-12-31 | 2009-07-09 | Syntaxin Limited | Rna delivery vehicles |
| US8470792B2 (en) | 2008-12-04 | 2013-06-25 | Opko Pharmaceuticals, Llc. | Compositions and methods for selective inhibition of VEGF |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997020579A3 (en) | 1997-09-25 |
| GB9524807D0 (en) | 1996-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100389820C (en) | Therapeutics containing botulinum neurotoxin | |
| US20170007669A1 (en) | Peptide-mediated delivery of active agents across the blood-brain barrier | |
| KR100852821B1 (en) | Therapeutic composition comprising botulinum neurotoxin | |
| Maksymowych et al. | Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade | |
| US8580745B2 (en) | Composition for therapeutic and cosmetic botulinum toxin | |
| JP2544968B2 (en) | Plasma and recombinant protein formulations in high ionic media | |
| US20110002914A1 (en) | Hybrid tetnus toxoid proteins that migrate retrogradely and transynaptically into the cns | |
| KR20030009431A (en) | Method for treating pain by peripheral administration of a neurotoxin | |
| KR20010031236A (en) | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents | |
| NZ541591A (en) | Method for the treatment of cerebral ischaemia and use of erythropodietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| AU6505796A (en) | Mucosal delivery of polynucleotides | |
| WO1997020579A2 (en) | Novel compounds and use | |
| EP1107722B1 (en) | A method for the treatment of staphylococcal infection | |
| US20250064940A1 (en) | Degradable lipid compound for active molecule delivery and nanocomplex thereof | |
| Manchanda et al. | Fabrication of advanced parenteral drug-delivery systems | |
| EP1064950B1 (en) | Remedies for hepatitis | |
| US20200009221A1 (en) | Methods for inhibiting necrosis | |
| JP2009514898A (en) | Treatment and prevention of adverse liver conditions using gallium | |
| WO2021005493A1 (en) | Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders | |
| JPH04275231A (en) | Method of using super oxide dismutase for prevention and treatment of organic rejection for critical patient having multiple injury as a result of accident | |
| JPH06340549A (en) | Therapeutic agent for feline respiratory organ disease and therapeutic method using the therapeutic agent | |
| US20020099005A1 (en) | Mucin comprising vehicle for the transport of biologically-active agents | |
| CN118021828A (en) | Use of compound 0449-0141 as NDM-1 inhibitor in antibacterial | |
| CN118021802A (en) | Application of compound 0683-0042 as NDM-1 inhibitor in antibacterial | |
| Schulz-Aellen et al. | Perspectives in the Detection and Treatment of Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520998 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |